Pharmaceuticals

As CFO Dave Denton departs for the consumer goods sector, Pfizer taps a 20-year veteran for the interim role, signaling continuity amid a crucial post-acquisition phase.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

German biotech Mallia Aesthetics reports impressive results for its hormone-free hair serum, but the real story lies in its resilient, science-first strategy.

After three decades, a new class of therapy for a rare liver disease lands in Singapore, rewriting the rules of care by targeting patient suffering, not just lab results.

Iceland's Alvotech secured a crucial capital infusion. It's a high-stakes play to survive financial pressures and compete in the next wave of affordable medicine.

A new report projects the wellness market will hit $12.9T by 2031. This isn't just about yoga mats; it's a tech-fueled, Asia-led economic realignment.

After a 20-year drought, positive Phase 3 data for oral olorofim signals a safer, potent new option against a deadly fungus, promising a major market shake-up.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.

Healthcare firm Cosmos Health is diversifying into the crowded skincare market with a DTC brand. Can its science-first approach disrupt the beauty industry?

AB Science has secured a US patent until 2042 for masitinib, a targeted therapy for advanced prostate cancer, offering new hope where few options exist.

Model N's acquisition of Kalderos targets the chaotic 340B drug discount program, a system where 99% of pharma leaders lack real-time data visibility.

A new network aims to speed up clinical trials by recruiting patients from med spas and longevity clinics. Is this the future of medicine or a risky new frontier?

With 180-day exclusivity, Lupin's generic hypertension drug launch is set to disrupt a $53M market, highlighting a masterclass in pharmaceutical strategy.

A new report reveals which cannabis brands dominate AI search, just as federal rescheduling creates chaos and opportunity. But with AI often refusing to answer, who wins?

Hearst and NYU Langone's star-studded Health Lab reveals a strategic pivot from fitness to holistic wellness, tapping a new market of longevity and vulnerability.

Bristol Myers Squibb appoints Mayada Al-Ahmad, a 24-year pharma veteran, to lead its Saudi and Gulf operations, aligning with the region's ambitious health goals.

A key regulatory win in Abu Dhabi opens a new international front for NeOnc's war on brain tumors, backed by novel science and significant insider buying.

A new partnership aims to replace needles with pills for a powerful class of drugs, using advanced AI to solve a multi-billion dollar challenge in medicine.

Laprophan's acquisition of Rivopharm is more than a deal; it's a strategic blueprint for emerging market players aiming for the global pharmaceutical stage.